Literature DB >> 14633668

Novel magnetic resonance imaging contrasts for monitoring response to gene therapy in rat glioma.

Olli H J Gröhn1, Piia K Valonen, Kimmo K Lehtimäki, Tuula H Väisänen, Mikko I Kettunen, Seppo Ylä-Herttuala, Risto A Kauppinen, Michael Garwood.   

Abstract

Magnetic resonance imaging relaxation times, T(1rho) and Carr-Purcell T(2) (CP-T(2)), were measured in a glioma herpes simplex virus-thymidine kinase gene therapy model. In treated tumors with >50% cell death by histology, T(1rho) and CP-T(2) measured with short spacing (tau(CP)) between centers of adiabatic refocusing pulses showed similar enhanced sensitivity to cytotoxic cell damage over CP-T(2) measured with long tau(CP) (long-tau(CP) T(2): 54.3 +/- 0.7 and 55.4 +/- 1.2 ms, P = 0.30; short-tau(CP) T(2): 61.3 +/- 1.0 and 64.2 +/- 1.1 ms, P < 0.05 before and day 2 of treatment, respectively). Without treatment, long-tau(CP) T(2) provided the most pronounced contrast between tumor and normal cerebral tissue. These data demonstrate that endogenous T(2) contrast can be modulated and extended in a manner likely to be clinically important.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633668

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

2.  Glioma cell density in a rat gene therapy model gauged by water relaxation rate along a fictitious magnetic field.

Authors:  Timo Liimatainen; Alejandra Sierra; Timothy Hanson; Dennis J Sorce; Seppo Ylä-Herttuala; Michael Garwood; Shalom Michaeli; Olli Gröhn
Journal:  Magn Reson Med       Date:  2011-06-30       Impact factor: 4.668

Review 3.  Imaging in neurooncology.

Authors:  Andreas H Jacobs; Lutz W Kracht; Axel Gossmann; Maria A Rüger; Anne V Thomas; Alexander Thiel; Karl Herholz
Journal:  NeuroRx       Date:  2005-04

4.  Transforming thymidine into a magnetic resonance imaging probe for monitoring gene expression.

Authors:  Amnon Bar-Shir; Guanshu Liu; Yajie Liang; Nirbhay N Yadav; Michael T McMahon; Piotr Walczak; Sridhar Nimmagadda; Martin G Pomper; Keri A Tallman; Marc M Greenberg; Peter C M van Zijl; Jeff W M Bulte; Assaf A Gilad
Journal:  J Am Chem Soc       Date:  2013-01-16       Impact factor: 15.419

5.  Water spin dynamics during apoptotic cell death in glioma gene therapy probed by T1rho and T2rho.

Authors:  A Sierra; S Michaeli; J-P Niskanen; P K Valonen; H I Gröhn; S Ylä-Herttuala; M Garwood; O H Gröhn
Journal:  Magn Reson Med       Date:  2008-06       Impact factor: 4.668

6.  Spin-lock imaging of intrinsic susceptibility gradients in tumors.

Authors:  Zhongliang Zu; Vaibhav Janve; John C Gore
Journal:  Magn Reson Med       Date:  2019-12-27       Impact factor: 4.668

Review 7.  Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring: preclinical and clinical approaches.

Authors:  Risto A Kauppinen; Andrew C Peet
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

8.  Early-stage imaging of nanocarrier-enhanced chemotherapy response in living subjects by scalable photoacoustic microscopy.

Authors:  Liming Nie; Peng Huang; Weitao Li; Xuefeng Yan; Albert Jin; Zhe Wang; Yuxia Tang; Shouju Wang; Xiaofen Zhang; Gang Niu; Xiaoyuan Chen
Journal:  ACS Nano       Date:  2014-11-21       Impact factor: 15.881

9.  Correcting for imaging gradients-related bias of T2 relaxation times at high-resolution MRI.

Authors:  Natalie Bnaiahu; Noam Omer; Ella Wilczynski; Shir Levy; Tamar Blumenfeld-Katzir; Noam Ben-Eliezer
Journal:  Magn Reson Med       Date:  2022-06-06       Impact factor: 3.737

Review 10.  Applying metabolomics to understand the aggressive phenotype and identify novel therapeutic targets in glioblastoma.

Authors:  Kamran A Ahmed; Prakash Chinnaiyan
Journal:  Metabolites       Date:  2014-08-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.